Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report)'s share price was up 7.1% during trading on Wednesday . The stock traded as high as $15.56 and last traded at $15.45. Approximately 196,029 shares changed hands during trading, a decline of 76% from the average daily volume of 815,789 shares. The stock had previously closed at $14.43.
Analysts Set New Price Targets
Several brokerages have recently issued reports on ZNTL. HC Wainwright reiterated a "buy" rating and set a $46.00 price target on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush upped their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a "neutral" rating in a report on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Zentalis Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $38.57.
View Our Latest Analysis on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Up 8.2 %
The business has a 50-day simple moving average of $13.63 and a 200-day simple moving average of $14.68. The stock has a market cap of $1.11 billion, a P/E ratio of -3.44 and a beta of 1.73.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.09. On average, analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.
Insider Activity at Zentalis Pharmaceuticals
In other news, CFO Melissa B. Epperly sold 2,573 shares of the firm's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the sale, the chief financial officer now owns 451,449 shares in the company, valued at $5,164,576.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 6.10% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Ameritas Investment Partners Inc. boosted its stake in shares of Zentalis Pharmaceuticals by 10.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,057 shares of the company's stock valued at $114,000 after purchasing an additional 376 shares in the last quarter. US Bancorp DE lifted its holdings in Zentalis Pharmaceuticals by 88.7% during the 2nd quarter. US Bancorp DE now owns 887 shares of the company's stock valued at $25,000 after purchasing an additional 417 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Zentalis Pharmaceuticals by 1.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,404 shares of the company's stock valued at $857,000 after buying an additional 569 shares in the last quarter. MetLife Investment Management LLC grew its stake in Zentalis Pharmaceuticals by 2.4% during the second quarter. MetLife Investment Management LLC now owns 25,544 shares of the company's stock worth $721,000 after buying an additional 608 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Zentalis Pharmaceuticals by 22.9% during the second quarter. Royal Bank of Canada now owns 3,296 shares of the company's stock worth $93,000 after buying an additional 615 shares in the last quarter.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
